Fluoxetine Mechanism and Clinical Implications

Primary Mechanism of Action

Fluoxetine selectively inhibits the serotonin transporter, blocking reuptake of serotonin at the synaptic cleft, which increases serotonin availability, according to the American Academy of Child and Adolescent Psychiatry 1
The blockade eventually leads to downregulation of inhibitory serotonin autoreceptors, heightening serotonergic neuronal firing rates and increasing serotonin release, as reported by the American Academy of Child and Adolescent Psychiatry 1
The multistep process explains the delayed onset of therapeutic effects seen with fluoxetine treatment, as noted by the American Academy of Child and Adolescent Psychiatry 1

Fluoxetine's selective serotonergic action makes it useful for treating various conditions including depression, OCD, and anxiety disorders, according to the American Academy of Child and Adolescent Psychiatry 1
Its activating profile may be beneficial for patients with fatigue but should be avoided in those with significant anxiety, agitation, or insomnia, as suggested by Praxis Medical Insights 2
Morning administration is recommended to minimize insomnia due to its activating properties, as recommended by Praxis Medical Insights 2

CYP2D6 genetic variations can significantly affect fluoxetine metabolism and plasma concentrations, as reported by the Mayo Clinic 3
Poor metabolizers of CYP2D6 may experience 3.9-11.5 fold higher area under the curve compared to extensive metabolizers, according to the Mayo Clinic 3
Long-term fluoxetine use at 20 mg/day can convert approximately 43% of extensive metabolizers to poor metabolizers through enzyme inhibition, as noted by the Mayo Clinic 3
The FDA has issued safety labeling changes for fluoxetine regarding QT prolongation risk in CYP2D6 poor metabolizers, as reported by the Mayo Clinic 3

Fluoxetine has shown potential benefit in cognitive impairment after cancer treatment through its promotion of hippocampal neurogenesis, as noted by the British Medical Journal 4